Search
mirvetuximab soravtansine-gynx (Elahere)
Indications:
- folate receptor alpha-positive, platinum-resistant cancers
- ovarian cancer, fallopian tube cancer, peritoneal cancer [1]
Dosage:
- 6 mg/kg (based on adjusted ideal body weight) IV infusion every 3 weeks
- 5 mg/mL injection (20 mL)
Adverse effects:
- common (>= 20%)
- vision impairment, keratopathy, dry eye*
- nausea, abdominal pain, diarrhea, constipation
- fatigue, peripheral neuropathy
- increased serum AST, serum ALT, & serum alkaline phosphatase
- decreased leukocyte count, neutrophil count, lymphocyte count, & blood hemoglobin
- decreased serum magnesium & serum albumin
* boxed warning of ocular toxicity
Mechanism of action:
- monoclonal antibody directed against folate receptor alpha linked to a microtubule inhibitor conjugate
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- FDA Drug Approvals. Nov 14, 2022
FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRa positive,
platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant
- Otto MA
FDA Approves Mirvetuximab Soravtansine for Folate Receptor Alpha-Positive Ovarian
Cancer.
Medscape. Nov 15, 2022
https://www.medscape.com/viewarticle/984055
- Moore KN, Oza AM, Colombo N et al
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy
in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
Ann Oncol. 2021 Jun;32(6):757-765.
PMID: 33667670 Clinical Trial.
https://www.annalsofoncology.org/article/S0923-7534(21)00157-5/fulltext